Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine mini lozenge for acute cigarette craving
NCT01506908Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Primary completion
- Dec 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nicotine polacrilex in Tobacco Use Disorder (TUD), sponsored by GSK. Primary endpoint: Change From Post-cue Baseline in Nicotine Craving. Started Sep 2011; status: completed.
02
Drugs
nicotine polacrilex
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT01506908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01506908.